Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQuantum Data Regulatory News (MAST)

  • There is currently no data for MAST

Shares issue

22 May 2023 15:00

RNS Number : 2348A
Mast Energy Developments PLC
22 May 2023
Β 

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

Share code on the LSE: MAST

ISIN: GB00BMBSCV12

('MED' or 'the Company')

Β 

Dated: 22 May 2023

Β 

Mast Energy Developments PLC ('MED' or 'the Company')

Β 

Shares issue

Β 

Mast Energy Developments PLC, theΒ UK-based multi-asset owner, developer, and operator in the rapidly growing flexible power market has today allotted 11,666,890 new MED shares of Β£0.001 each (the "Conversion Shares") following receipt of conversion notices from the institutional lender group under the terms of the recent reprofiling agreement (the "Reprofiling Agreement") on the balance of its outstanding loan facilities announced on its RNS of 17 May 2023.

Β 

The shares are being issued in respect of Β£34,662.125 in accrued interest and Β£50,000 in principal payment (total of Β£84,663.125) at an exercise price of Β£0.0072567 per Conversion Share in accordance with the terms of the Reprofiling Agreement.

Β 

Application will be made for the Conversion Shares to be admitted to the Standard List segment of the Official List and to trading on the main market of the London Stock Exchange plc ("Admission"). It is expected that Admission will become effective and dealings in the Fee Shares will commence at 8.00am on, or around, 26 May 2023.

Β 

Following Admission, the total issued share capital of the Company will consist of 229,119,619 ordinary shares in issue and this figure may be used by shareholders as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. The shareholding of MED's largest shareholder, Kibo Mining (Cyprus) Limited will reduce from 57.86% to 54.91% following Admission.

Β 

ENDS

This announcement contains inside information for the purposes of the UK version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ('UK MAR'). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Β 

For further information please visit www.med.energy or contact:

Β 

Pieter KrΓΌgel

Info@med.energy

Mast Energy

Developments PLC

CEO

Jon Belliss

+44 (0)20 7399 9425

Novum Securities

Corporate Broker

Zainab Slemang van Rijmenant

zainab@lifacommunications.com

Lifa Communications

Investor & Media Relations Advisor

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
IOESEUFDEEDSELI
Date   Source Headline
23rd Oct 20237:00 amRNSMED Binding JVA Completion Update
12th Oct 20232:03 pmRNSHolding(s) in Company
12th Oct 20232:01 pmRNSHolding(s) in Company
12th Oct 20232:00 pmRNSHolding(s) in Company
5th Oct 20237:00 amRNSIssue of Equity
22nd Sep 20237:00 amRNSMED Binding JVA Completion Update
1st Sep 20237:00 amRNSMED Binding Joint Venture Completion Update
25th Aug 20237:00 amRNSHalf-year Report
9th Aug 20232:16 pmRNSHolding(s) in Company
4th Aug 20237:00 amRNSMED Binding Joint Venture Completion Update
12th Jul 20231:15 pmRNSJoint Venture
6th Jun 20231:09 pmRNSResult of AGM
23rd May 20232:30 pmRNSIssue of Equity
22nd May 20233:00 pmRNSShares issue
18th May 20237:00 amRNSJV & Investment. New Broker & Loan Reprofiling
16th May 20231:15 pmRNSNotice of AGM
4th May 20237:00 amRNSQ1 Corporate Presentation and Website Update
28th Apr 20237:00 amRNSResults for the year ended 31 December 2022
27th Feb 20237:00 amRNSPyebridge Update
20th Dec 20224:40 pmRNSSecond Price Monitoring Extn
20th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20222:05 pmRNSSecond Price Monitoring Extn
20th Dec 20222:00 pmRNSPrice Monitoring Extension
16th Dec 20227:00 amRNSPyebridge SPA Deferred Consideration Settlement
15th Dec 20222:00 pmRNSTR-1: Notification of major holdings
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
8th Dec 20227:00 amRNSBordesley Update
17th Nov 20227:00 amRNSCorporate Presentation
3rd Nov 20227:00 amRNSFurther Funding Secured
31st Oct 20221:41 pmRNSClarification of Pyebridge Trading Update
27th Oct 20224:41 pmRNSSecond Price Monitoring Extn
27th Oct 20224:35 pmRNSPrice Monitoring Extension
27th Oct 20222:05 pmRNSSecond Price Monitoring Extn
27th Oct 20222:00 pmRNSPrice Monitoring Extension
24th Oct 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20222:05 pmRNSSecond Price Monitoring Extn
24th Oct 20222:00 pmRNSPrice Monitoring Extension
24th Oct 202211:05 amRNSSecond Price Monitoring Extn
24th Oct 202211:00 amRNSPrice Monitoring Extension
24th Oct 20229:05 amRNSSecond Price Monitoring Extn
24th Oct 20229:00 amRNSPrice Monitoring Extension
21st Oct 20224:40 pmRNSSecond Price Monitoring Extn
21st Oct 20224:35 pmRNSPrice Monitoring Extension
21st Oct 20222:06 pmRNSSecond Price Monitoring Extn
21st Oct 20222:00 pmRNSPrice Monitoring Extension
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
20th Oct 20224:41 pmRNSSecond Price Monitoring Extn
20th Oct 20224:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.